Among them, the TLR3 agonist Polyinosinic-polycytidylic acid (Poly I:C), a classic TRIF pathway activator, can directly stimulate tumor cells to release Immunogenic Cell Death (ICD)-associated molecules like HMGB1 (160), while also promoting IFN-I production by DCs, enhancing cross-priming effects. Here, TLR3 is linked to neoplasm.